id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-P-1794-0001,FDA,FDA-2026-P-1794,"Suitability Petition from Lachman Consulting Services, Inc.",Other,Petition(s),2026-02-18T05:00:00Z,2026,2,2026-02-18T05:00:00Z,,2026-02-19T01:50:40Z,,1,0,09000064b91b9267
FDA-2026-P-1794-0002,FDA,FDA-2026-P-1794,"Acknowledgment Letter from FDA DMB to Lachman Consulting Services, Inc.",Other,Acknowledgement Letter/Receipt,2026-02-18T05:00:00Z,2026,2,2026-02-18T05:00:00Z,,2026-02-19T01:50:46Z,,0,0,09000064b91b9269
FDA-2026-P-1794-0007,FDA,FDA-2026-P-1794,Attachment 5 Advances in Therapy,Supporting & Related Material,Background Material,2026-02-18T05:00:00Z,2026,2,,,2026-02-19T01:52:47Z,,0,0,09000064b91bb01b
FDA-2026-P-1794-0004,FDA,FDA-2026-P-1794,Attachment 2 Current Package Insert for Xarelto,Supporting & Related Material,Background Material,2026-02-18T05:00:00Z,2026,2,,,2026-02-19T01:52:36Z,,0,0,09000064b91b9bfd
FDA-2026-P-1794-0006,FDA,FDA-2026-P-1794,Attachment 4 Blood Advances,Supporting & Related Material,Background Material,2026-02-18T05:00:00Z,2026,2,,,2026-02-19T01:52:44Z,,0,0,09000064b91bb01a
FDA-2026-P-1794-0005,FDA,FDA-2026-P-1794,Attachment 3 Proposed Package Insert Rivaroxaban ODT,Supporting & Related Material,Background Material,2026-02-18T05:00:00Z,2026,2,,,2026-02-19T01:52:40Z,,0,0,09000064b91b9bfe
FDA-2026-P-1794-0003,FDA,FDA-2026-P-1794,Attachment 1 Copy of Current Orange Book Listing for RLD Xarelto,Supporting & Related Material,Background Material,2026-02-18T05:00:00Z,2026,2,,,2026-02-19T01:52:31Z,,0,0,09000064b91b9bfc